Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$481.71 USD
+5.56 (1.17%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $481.72 +0.01 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 3,619.60 | 3,322.00 | 2,342.10 | 2,711.65 | 1,176.81 |
Depreciation/Amortization & Depletion | 181.30 | 148.30 | 125.60 | 109.52 | 106.94 |
Net Change from Assets/Liabilities | -265.70 | 340.80 | -105.20 | -54.45 | -66.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.10 | 318.80 | 281.00 | 486.80 | 351.68 |
Net Cash From Operating Activities | 3,537.30 | 4,129.90 | 2,643.50 | 3,253.51 | 1,569.33 |
Property & Equipment | -200.40 | -204.70 | -235.00 | -259.80 | -75.45 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -295.90 | 0.00 | 0.00 | -1,154.21 |
Investments | -2,883.30 | 179.50 | -28.90 | 359.19 | -5.65 |
Other Investing Activities | -58.00 | 0.00 | -77.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -3,141.70 | -321.10 | -340.90 | 99.39 | -1,235.32 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -293.00 | 186.30 | -1,323.40 | -274.19 | 151.23 |
Issuance (Repayment) of Debt | -43.10 | -85.50 | -24.40 | -29.02 | -35.01 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -226.10 | -168.50 | -130.20 | -202.07 | 10.55 |
Net Cash from Financing Activities | -562.20 | -67.70 | -1,478.00 | -505.28 | 126.77 |
Effect of Exchange Rate Changes | 26.90 | -29.20 | -13.40 | 20.55 | 1.64 |
Net Change In Cash & Equivalents | -139.70 | 3,711.90 | 811.20 | 2,868.16 | 462.43 |
Cash at Beginning of Period | 10,512.00 | 6,800.10 | 5,988.90 | 3,120.68 | 2,658.25 |
Cash at End of Period | 10,372.30 | 10,512.00 | 6,800.10 | 5,988.85 | 3,120.68 |
Diluted Net EPS | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 |
Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -2,494.00 | 1,099.60 | 3,619.60 | 2,650.80 |
Depreciation/Amortization & Depletion | NA | 107.50 | 53.50 | 181.30 | 122.30 |
Net Change from Assets/Liabilities | NA | -112.10 | 129.30 | -265.70 | 573.20 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 51.60 | 24.20 | 2.10 | -43.60 |
Net Cash From Operating Activities | NA | -2,447.00 | 1,306.60 | 3,537.30 | 3,302.70 |
Property & Equipment | NA | -137.40 | -68.40 | -200.40 | -142.30 |
Acquisition/ Disposition of Subsidiaries | NA | -258.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -2,002.00 | -1,888.00 | -2,883.30 | -2,112.90 |
Other Investing Activities | NA | -202.70 | -180.00 | -58.00 | 0.00 |
Net Cash from Investing Activities | NA | -2,600.10 | -2,136.40 | -3,141.70 | -2,255.20 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -379.60 | -114.30 | -293.00 | -189.90 |
Issuance (Repayment) of Debt | NA | -26.90 | -13.20 | -43.10 | -32.90 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -309.60 | -230.00 | -226.10 | -219.60 |
Net Cash from Financing Activities | NA | -716.10 | -357.50 | -562.20 | -442.40 |
Effect of Exchange Rate Changes | NA | -18.10 | -15.60 | 26.90 | -0.50 |
Net Change In Cash & Equivalents | NA | -5,781.30 | -1,202.90 | -139.70 | 604.60 |
Cash at Beginning of Period | NA | 10,372.30 | 10,372.30 | 10,512.00 | 10,512.00 |
Cash at End of Period | NA | 4,591.00 | 9,169.40 | 10,372.30 | 11,116.60 |
Diluted Net EPS | NA | -13.92 | 4.21 | 3.71 | 3.97 |